Donatello Salvatore

Dr. Donatello Salvatore

Ospedale San Carlo, Potenza
orcid

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2009 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
RBR. Buzzetti
R. Buzzetti
DSDonatello Salvatore
Donatello Salvatore
EBE. Baldo
E. Baldo
MFM.P. Forneris
M.P. Forneris
VLV. Lucidi
V. Lucidi
GMG. Mastella
G. Mastella

1 March 2011 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
DSDonatello Salvatore
Donatello Salvatore
RBRoberto Buzzetti
Roberto Buzzetti
EBErmanno Baldo
Ermanno Baldo
MFMaria Pia Forneris
Maria Pia Forneris
VLVincenzina Lucidi
Vincenzina Lucidi
GMGianni Mastella
Gianni Mastella

13 October 2016 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
VTVito Terlizzi
Vito Terlizzi
GCGiuseppe Castaldo
Giuseppe Castaldo
DSDonatello Salvatore
Donatello Salvatore
MLMarco Lucarelli
Marco Lucarelli
VRValeria Raia
Valeria Raia
FAFelice Amato
Felice Amato
Background The effect of complex alleles in cystic fibrosis (CF) is poorly defined for the lack of functional studies. Objectives To describe the genotype–phenotype correlation and the results of either in vitro and ex vivo studies performed on nasal epithelial cells (NEC) in a cohort of patients with CF carrying cystic fibrosis transmembrane conductance regulator (CFTR) complex alleles. Methods We studied 70 homozygous, compound heterozygous or heterozygous for CFTR mutations: p.[Arg74Trp;Val201Met;Asp1270Asn], n=8; p.[Ile148Thr;Ile1023_Val1024del], n=5; p.[Arg117Leu;Leu997Phe], n=6; c.[1210-34TG[12];1210-12T[5];2930C>T], n=3; p.[Arg74Trp;Asp1270Asn], n=4; p.Asp1270Asn, n=2; p.Ile148Thr, n=6; p.Leu997Phe, n=36. In 39 patients, we analysed the CFTR gating activity on NEC in comparison with patients with CF (n=8) and carriers (n=4). Finally, we analysed in vitro the p.[Arg74Trp;Val201Met;Asp1270Asn] complex allele. Results The p.[Ile148Thr;Ile1023_Val1024del] caused severe CF in five compound heterozygous with a class I–II mutation. Their CFTR activity on NEC was comparable with patients with two class I–II mutations (mean 7.3% vs 6.9%). The p.[Arg74Trp;Asp1270Asn] and the p.Asp1270Asn have scarce functional effects, while p.[Arg74Trp;Val201Met;Asp1270Asn] caused mild CF in four of five subjects carrying a class I–II mutation in trans, or CFTR-related disorders (CFTR-RD) in three having in trans a class IV–V mutation. The p.[Arg74Trp;Val201Met;Asp1270Asn] causes significantly (pT] and a class I–II mutation had mild CF or CFTR-RD (gating activity: 18.5–19.0%). Conclusions The effect of complex alleles partially depends on the mutation in trans. Although larger studies are necessary, the CFTR activity on NEC is a rapid contributory tool to classify patients with CFTR dysfunction.

16 February 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VCVincenzo Carnovale
Vincenzo Carnovale
PIPaola Iacotucci
Paola Iacotucci
Vito TerlizziVito Terlizzi
Vito Terlizzi
CCCarmela Colangelo
Carmela Colangelo
LFLorenza Ferrillo
Lorenza Ferrillo
DSDonatello Salvatore
Donatello Salvatore
Background: Elexacaftor/tezacaftor/ivacaftor (ETI) is the newest cystic fibrosis transmembrane conductance regulator (CFTR) modulator drug approved for the treatment of patients with cystic fibrosis (pwCF) aged ≥6 years with at least one copy of the F508del mutation (F) in the CFTR gene or another mutation that is responsive to treatment with ETI. This study determined the effectiveness and safety of ETI in a cohort of severely affected pwCF with an F/F genotype. Methods: Retrospective observational study in F/F pwCF treated for 48 weeks, enrolled in an ETI managed access program available to subjects with advanced lung disease (ppFEV1 < 40). Twenty-six patients from three centres were included. The main outcomes included lung function, sweat chloride concentration (SCC), nutrition, frequency of pulmonary exacerbations (PEx), CFQ-R, and safety. Results: ppFEV1 improved by 12.06 (95%CI 8.54, 15.57) from baseline after 4 weeks of treatment with ETI, 15.32 (11.3, 19.34) after 24 weeks, and 14.48 (10.64, 18.32) after 48 weeks. The increase in FEV1 was accompanied by a decrease in SCC, improvement of BMI, and noticeable reduction in PEx. An overall good safety profile was observed. Conclusions: In F/F pwCF with advanced lung disease with an F/F genotype, ETI was safe and associated with clinical improvement.

1 November 2021 in Respiratory Medicine
Verified
Journal Article
Closed access
VCVincenzo Carnovale
Vincenzo Carnovale
PIPaola Iacotucci
Paola Iacotucci
VTVito Terlizzi
Vito Terlizzi
CCCarmela Colangelo
Carmela Colangelo
PMPietro Medio
Pietro Medio
DSDonatello Salvatore
Donatello Salvatore

1 September 2006 in Journal of Hospital Infection
Verified
Journal Article
Closed access
FFFilippo Festini
Filippo Festini
RBR. Buzzetti
R. Buzzetti
CBC. Bassi
C. Bassi
CBC. Braggion
C. Braggion
DSDonatello Salvatore
Donatello Salvatore
GMG. Mastella
G. Mastella